What is HC Wainwright's Estimate for MPLT Q1 Earnings?

Key Points

• HC Wainwright's R. Selvaraju forecasts Maplight will report ($0.98) EPS for Q1 2026 and ($4.34) for FY2026, and assigns the stock a Buy rating with a $45.00 price target.
• Maplight last reported a large Q1 miss, posting ($2.47) EPS versus consensus ($1.05), while the street consensus remains a "Moderate Buy" with an average target of $34.43.

Maplight Therapeutics, Inc. (NASDAQ:MPLT - Free Report) - HC Wainwright issued their Q1 2026 earnings estimates for Maplight Therapeutics in a research report issued on Monday, May 4th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.98) per share for the quarter. HC Wainwright has a "Buy" rating and a $45.00 price objective on the stock. The consensus estimate for Maplight Therapeutics' current full-year earnings is ($3.87) per share. HC Wainwright also issued estimates for Maplight Therapeutics' Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($1.21) EPS, FY2026 earnings at ($4.34) EPS, Q1 2027 earnings at ($1.35) EPS, Q2 2027 earnings at ($1.40) EPS, Q3 2027 earnings at ($1.30) EPS, Q4 2027 earnings at ($1.22) EPS and FY2027 earnings at ($5.25) EPS.

Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last issued its earnings results on Thursday, March 26th. The company reported ($2.47) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by ($1.42).

A number of other equities research analysts have also weighed in on the stock. Weiss Ratings began coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They set a "sell (e)" rating for the company. Needham & Company LLC assumed coverage on Maplight Therapeutics in a research report on Wednesday, April 8th. They set a "buy" rating and a $37.00 price target on the stock. TD Cowen started coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They set a "buy" rating on the stock. Canaccord Genuity Group assumed coverage on Maplight Therapeutics in a research note on Thursday, March 19th. They issued a "buy" rating and a $35.00 target price on the stock. Finally, Wall Street Zen downgraded Maplight Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $34.43.

Maplight Therapeutics Price Performance

Shares of NASDAQ MPLT opened at $27.92 on Wednesday. The stock has a market capitalization of $1.19 billion and a P/E ratio of -0.70. Maplight Therapeutics has a 1-year low of $12.24 and a 1-year high of $33.28. The stock has a 50-day moving average of $22.39.

Insider Activity

In other Maplight Therapeutics news, Director George Pavlov bought 10,658 shares of the company's stock in a transaction dated Wednesday, February 18th. The shares were bought at an average price of $17.48 per share, for a total transaction of $186,301.84. Following the acquisition, the director directly owned 10,658 shares of the company's stock, valued at approximately $186,301.84. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Gillis sold 51,900 shares of the company's stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $29.74, for a total transaction of $1,543,506.00. Following the completion of the transaction, the insider owned 199,154 shares in the company, valued at approximately $5,922,839.96. This represents a 20.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders bought 39,124 shares of company stock worth $693,846 and sold 148,431 shares worth $4,040,428.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Strs Ohio acquired a new position in shares of Maplight Therapeutics during the 4th quarter worth $53,000. Bank of New York Mellon Corp increased its holdings in shares of Maplight Therapeutics by 10.1% during the 1st quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company's stock worth $802,000 after purchasing an additional 3,608 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new position in Maplight Therapeutics during the fourth quarter valued at about $70,000. New York State Common Retirement Fund bought a new stake in shares of Maplight Therapeutics during the fourth quarter valued at approximately $93,000. Finally, MetLife Investment Management LLC acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at $172,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.